Get started
Work

Abstract GS1-09: Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: Primary results from ASCENT-07

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-gs1-09
Authors: K. L. Jhaveri, Y. Park, C. Barrios, G. Curigliano, H. Iwata, J. Cortés, D. Loirat, T. Pascual, Z. Shao, C. Araneda, T. Yamashita, M. Tapia, P. Cinar, S. Lam, X. Ren, W. Verret, J. Kwan, K. Punie, H. S. Rugo
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Samsung Medical Center, Sungkyunkwan University, Latin American Cooperative Oncology Group (LACOG), University of Milan, European Institute of Oncology, Nagoya City University, MedSIR (Spain), Universidad Europea de Madrid, Institut Curie, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Fudan University, Fudan University Shanghai Cancer Center, Kanagawa Cancer Center, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Gilead Sciences (United States), Ziekenhuis aan de Stroom, City of Hope
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129508286
Cites:
Cited by: 9
Related to: